Literature DB >> 16116962

Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer.

Yulong Zhou1, Yongjian Xu, Zhenxiang Zhang.   

Abstract

To examine the deletion and point mutation of WWOX (WW domain containing oxidoreductase) exons 6-8 in human non-small cell lung cancer and their possible relationship with pathological stages, tumor tissues and the corresponding normal tissues were obtained from 44 Chinese patients who had undergone surgery for non-small cell lung cancer. RNA was extracted from each sample and deletion and mutation of WWOX exons 6-8 were analyzed by RT-PCR and DNA sequencing. Our results showed that 28 of 44 (63.6%) lung cancer samples showed loss of WWOX exons 6-8 transcript and the deletion was detected in only 3 of 44 (6.8%) corresponding adjacent normal tissues (P < 0.05). The transcript sequencing analyses of the 16 lung cancer samples without transcript loss of WWOX exons 6-8 revealed no difference from the sequence of GenBank. Moreover, the deletion of WWOX exons 6-8 was significantly higher in the smokers when compared with the non-smokers. It is also higher in the men and squamous carcinomas than in women and adenocarcinomas (P < 0. 05). The deletion, however, was not found to be associated with pathological stages of the tumors. Our study documented a high incidence of deletion of WWOX exons 6-8 in non-small cell lung cancer in Chinese patients and suggested that the frequent loss of WWOX exons 6-8 might play an important role in the tumorigenesis of non-small cell lung cancer in Chinese. WWOX exons 6-8 may serves as a candidate molecular target of smoking carcinogenesis, and point mutation is not a predominant way of alteration of WWOX exons 6-8.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116962     DOI: 10.1007/BF02873566

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.

Authors:  A K Bednarek; C L Keck-Waggoner; R L Daniel; K J Laflin; P L Bergsagel; K Kiguchi; A J Brenner; C M Aldaz
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  Chromosomal fragile site FRA16D and DNA instability in cancer.

Authors:  M Mangelsdorf; K Ried; E Woollatt; S Dayan; H Eyre; M Finnis; L Hobson; J Nancarrow; D Venter; E Baker; R I Richards
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

3.  Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity.

Authors:  N S Chang; N Pratt; J Heath; L Schultz; D Sleve; G B Carey; N Zevotek
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

4.  WWOX: a candidate tumor suppressor gene involved in multiple tumor types.

Authors:  A J Paige; K J Taylor; C Taylor; S G Hillier; S Farrington; D Scott; D J Porteous; J F Smyth; H Gabra; J E Watson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

5.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.

Authors:  A K Bednarek; K J Laflin; R L Daniel; Q Liao; K A Hawkins; C M Aldaz
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

6.  Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus.

Authors:  P L Paris; J S Witte; P A Kupelian; H Levin; E A Klein; W J Catalona; G Casey
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

7.  Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells.

Authors:  K Ried; M Finnis; L Hobson; M Mangelsdorf; S Dayan; J K Nancarrow; E Woollatt; G Kremmidiotis; A Gardner; D Venter; E Baker; R I Richards
Journal:  Hum Mol Genet       Date:  2000-07-01       Impact factor: 6.150

8.  Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma.

Authors:  Chris I Huang; Donna Neuberg; Bruce E Johnson; Jeanne Y Wei; David C Christiani
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

9.  Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas.

Authors:  Katja Preussat; Christian Beetz; Michael Schrey; Robert Kraft; Stefan Wölfl; Rolf Kalff; Stephan Patt
Journal:  Neurosci Lett       Date:  2003-07-31       Impact factor: 3.046

10.  Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma.

Authors:  Tamotsu Kuroki; Francesco Trapasso; Takeshi Shiraishi; Hansjuerg Alder; Koshi Mimori; Masaki Mori; Carlo M Croce
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

View more
  5 in total

1.  The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.

Authors:  Ileana Aderca; Catherine D Moser; Manivannan Veerasamy; Ahmad H Bani-Hani; Ruben Bonilla-Guerrero; Kadra Ahmed; Abdirashid Shire; Sophie C Cazanave; Damian P Montoya; Teresa A Mettler; Lawrence J Burgart; David M Nagorney; Stephen N Thibodeau; Julie M Cunningham; Jin-Ping Lai; Lewis R Roberts
Journal:  J Hepatol       Date:  2008-06-09       Impact factor: 25.083

2.  Functional genetic variant of WW domain-containing oxidoreductase (WWOX) gene is associated with hepatocellular carcinoma risk.

Authors:  Hsiang-Lin Lee; Hsin-Lin Cheng; Yu-Fan Liu; Ming-Chih Chou; Shun-Fa Yang; Ying-Erh Chou
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

3.  Association between WWOX and the risk of malignant tumor, especially among Asians: evidence from a meta-analysis.

Authors:  Hao Yuan; Yang Wu; Jingjing Zhang; Guodong Shi; Dongfang Liu; Yuan He; Zipeng Lu; Pengfei Wu; Kuirong Jiang; Yi Miao
Journal:  Onco Targets Ther       Date:  2018-04-03       Impact factor: 4.147

4.  Effect of WW Domain-Containing Oxidoreductase Gene Polymorphism on Clinicopathological Characteristics of Patients with EGFR Mutant Lung Adenocarcinoma in Taiwan.

Authors:  Ju-Pi Li; Jinghua Tsai Chang; Po-Chung Ju; Ming-Hong Hsieh; Yu-Hua Chao; Thomas Chang-Yao Tsao; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2021-12-13       Impact factor: 3.390

5.  The WWOX/HIF1A Axis Downregulation Alters Glucose Metabolism and Predispose to Metabolic Disorders.

Authors:  Izabela Baryła; Ewa Styczeń-Binkowska; Elżbieta Płuciennik; Katarzyna Kośla; Andrzej K Bednarek
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.